Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Centocor, Inc. Quintiles |
---|---|
Information provided by: | Centocor, Inc. |
ClinicalTrials.gov Identifier: | NCT00643526 |
The main purpose of this study is to evaluate how well the autoinjector works in a group of people who are likely to use the autoinjector for injecting their medicine in the future. However, no active medicine is given by the autoinjector.
Condition | Intervention |
---|---|
Rheumatoid Arthritis and Psoriasis Ankylosing Spondylitis Psoriatic Arthritis |
Device: Centocor autoinjector is a prefilled, spring-powered, disposable device for the subcutaneous administration of liquid biologic drug products. |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Parallel Assignment |
Official Title: | An Open-Label, Randomized, Validation Study to Establish That the Design, Functionality, and Ergonomic Features of the Autoinjector Conform to Defined User Needs and Intended Use for Self-Administration by Subjects With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Psoriasis |
Estimated Enrollment: | 68 |
Study Start Date: | December 2007 |
Study Completion Date: | January 2008 |
The main purpose of this study is to evaluate how well the autoinjector works in a group of people who are likely to use the autoinjector for injecting their medicine in the future. However, no active medicine is given in the autoinjector. This device (called an autoinjector) automatically injects medicine under the skin with a sterile needle, and is similar to other types of autoinjectors currently being used for this purpose. This trial has been designed to make sure that people, who are likely to use this device, are able to self-inject and understand the training material. A total of 68 subjects took part in the study. About half (30 patients) will have either Rheumatoid Arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and the other half will have psoriasis (a type of skin disease), since this device will be used by patients with one of these diseases to inject their medication. The study is designed to have each patient complete 2 self-injections with the autoinjector in 2 different sites-one in the front of the thigh and one in the abdomen 2 inches away from the navel. The order of the first injection location is decided by randomization. The patient will have an equal chance of having the thigh or the abdomen as the first injection. The study staff will assess the subject's safety prior to the patient leaving the clinic.
Two prefilled, 1mL placebo autoinjectors for subcutaneous injection
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CR014914 |
Study First Received: | February 22, 2008 |
Last Updated: | March 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00643526 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Autoinjector Psoriasis Rheumatologic disorders |
Spinal Diseases Autoimmune Diseases Skin Diseases Collagen Diseases Arthritis, Psoriatic Spondylarthropathy Joint Diseases Arthritis, Rheumatoid Rheumatic Diseases Bone Diseases |
Musculoskeletal Diseases Psoriasis Arthritis Connective Tissue Diseases Spondylitis, Ankylosing Skin Diseases, Papulosquamous Spondylarthritis Spondylitis Ankylosis Spondylarthropathies |
Spinal Diseases Autoimmune Diseases Immune System Diseases Skin Diseases Arthritis, Psoriatic Joint Diseases Arthritis, Rheumatoid Rheumatic Diseases Infection Bone Diseases Bone Diseases, Infectious |
Musculoskeletal Diseases Psoriasis Arthritis Connective Tissue Diseases Spondylitis, Ankylosing Spondylarthritis Skin Diseases, Papulosquamous Spondylitis Ankylosis Spondylarthropathies |